Description
The advent of novel biologic medicines for the treatment of inflammatory bowel disease (IBD) has increased the availability of therapeutic options to induce and maintain remission in patients with this disease. They have become an important modality of treatment in IBD and the mainstay of therapy in patients with fistulising or perianal Crohn’s disease (CD).